Samsung Biologics Co Ltd (207940) — Cash Flow-to-Debt Ratio
Samsung Biologics Co Ltd (207940) has a Cash Flow-to-Debt Ratio of 0.10x as of September 2025, meaning its operating cash flow of ₩619.30 Billion could theoretically repay 0% of its total liabilities (₩6.16 Trillion) in one year. Explore Samsung Biologics Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Samsung Biologics Co Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Samsung Biologics Co Ltd across 11 annual periods. Also explore how large is Samsung Biologics Co Ltd's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Samsung Biologics Co Ltd (2014–2024)
Year-by-year debt coverage analysis for Samsung Biologics Co Ltd. For market capitalisation and broader financial context, see 207940 market cap.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.26x | ₩1.66 Trillion | ₩6.43 Trillion | ▼ -3.8% |
| 2023 | 0.27x | ₩1.67 Trillion | ₩6.22 Trillion | ▲ +113.7% |
| 2022 | 0.13x | ₩953.05 Billion | ₩7.60 Trillion | ▼ -17.8% |
| 2021 | 0.15x | ₩454.60 Billion | ₩2.98 Trillion | ▲ +37.8% |
| 2020 | 0.11x | ₩202.09 Billion | ₩1.83 Trillion | ▲ +1597.8% |
| 2019 | 0.01x | ₩10.15 Billion | ₩1.56 Trillion | ▲ +136.0% |
| 2018 | -0.02x | ₩-33.02 Billion | ₩1.82 Trillion | ▼ -138.7% |
| 2017 | 0.05x | ₩149.82 Billion | ₩3.21 Trillion | ▲ +357.3% |
| 2016 | -0.02x | ₩-62.66 Billion | ₩3.45 Trillion | ▲ +78.2% |
| 2015 | -0.08x | ₩-265.51 Billion | ₩3.19 Trillion | ▲ +44.2% |
| 2014 | -0.15x | ₩-108.30 Billion | ₩724.97 Billion | — |